193 related articles for article (PubMed ID: 24335535)
21. Quantification of [
Golla SS; Verfaillie SC; Boellaard R; Adriaanse SM; Zwan MD; Schuit RC; Timmers T; Groot C; Schober P; Scheltens P; van der Flier WM; Windhorst AD; van Berckel BN; Lammertsma AA
J Cereb Blood Flow Metab; 2019 Nov; 39(11):2172-2180. PubMed ID: 29897009
[TBL] [Abstract][Full Text] [Related]
22. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
23. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages.
Raposo N; Planton M; Péran P; Payoux P; Bonneville F; Lyoubi A; Albucher JF; Acket B; Salabert AS; Olivot JM; Hitzel A; Chollet F; Pariente J
Neurology; 2017 Aug; 89(7):697-704. PubMed ID: 28724587
[TBL] [Abstract][Full Text] [Related]
24. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
[TBL] [Abstract][Full Text] [Related]
25. Association Between Midlife Vascular Risk Factors and Estimated Brain Amyloid Deposition.
Gottesman RF; Schneider AL; Zhou Y; Coresh J; Green E; Gupta N; Knopman DS; Mintz A; Rahmim A; Sharrett AR; Wagenknecht LE; Wong DF; Mosley TH
JAMA; 2017 Apr; 317(14):1443-1450. PubMed ID: 28399252
[TBL] [Abstract][Full Text] [Related]
26. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
27. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
Landau SM; Fero A; Baker SL; Koeppe R; Mintun M; Chen K; Reiman EM; Jagust WJ
J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
[TBL] [Abstract][Full Text] [Related]
28. Validation of an (18)F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques.
Wey SP; Weng CC; Lin KJ; Yao CH; Yen TC; Kung HF; Skovronsky D; Kung MP
Nucl Med Biol; 2009 May; 36(4):411-7. PubMed ID: 19423009
[TBL] [Abstract][Full Text] [Related]
29. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
30. Dual-phase
Kuo HC; Hsiao IT; Hsieh CJ; Huang CY; Huang KL; Wai YY; Chuang WL; Kung MP; Chu YC; Yen TC; Lin KJ; Huang CC
J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
[TBL] [Abstract][Full Text] [Related]
31. Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study.
Doraiswamy PM; Sperling RA; Coleman RE; Johnson KA; Reiman EM; Davis MD; Grundman M; Sabbagh MN; Sadowsky CH; Fleisher AS; Carpenter A; Clark CM; Joshi AD; Mintun MA; Skovronsky DM; Pontecorvo MJ;
Neurology; 2012 Oct; 79(16):1636-44. PubMed ID: 22786606
[TBL] [Abstract][Full Text] [Related]
32. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
33. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
34. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
[TBL] [Abstract][Full Text] [Related]
35. Optimisation and usefulness of quantitative analysis of
Fakhry-Darian D; Patel NH; Khan S; Barwick T; Svensson W; Khan S; Perry RJ; Malhotra P; Carswell CJ; Nijran KS; Win Z
Br J Radiol; 2019 Sep; 92(1101):20181020. PubMed ID: 31017465
[TBL] [Abstract][Full Text] [Related]
36. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
37. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidenced on 18F-florbetapir (AV-45/Amyvid) positron emission tomography.
Wu KY; Hsiao IT; Chen CS; Chen CH; Hsieh CJ; Wai YY; Chang CJ; Tseng HJ; Yen TC; Liu CY; Lin KJ
Eur J Nucl Med Mol Imaging; 2014 Apr; 41(4):714-22. PubMed ID: 24233127
[TBL] [Abstract][Full Text] [Related]
38. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
39. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
40. Improved longitudinal [(18)F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction.
Brendel M; Högenauer M; Delker A; Sauerbeck J; Bartenstein P; Seibyl J; Rominger A;
Neuroimage; 2015 Mar; 108():450-9. PubMed ID: 25482269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
